Cognition Therapeutics, Inc.

The company is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. Many of these diseases currently have limited or no approved therapies. The company aims to develop disease-modifying treatments for patients with these degenerative disorders. Its lead product candidate is zervimesine, also known as CT1812, an orally delivered small molecule. Zervimesine is designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including β-amyloid (Aβ) and ɑ-synuclein, which are linked to diseases like Alzheimer's disease (AD) and dementia with Lewy bodies (DLB). The United States Adopted Name (USAN) Council adopted zervimesine as the USAN for CT1812 in December 2024. The company initially focused on developing zervimesine for AD, believing it displaces Aβ oligomers from neuronal receptors, potentially slowing synapse loss and cognitive decline in AD. Direct healthcare costs for AD and other dementias in the United States are estimated to exceed $350 billion, with approximately 7 million people diagnosed with AD in the U.S. and an estimated 35 million globally. Top-line results from the Phase 2 COG0201 (SHINE) study of zervimesine in mild-to-moderate AD were reported in 2024. Enrollment is ongoing in the COG0203 (START) Phase 2 study of zervimesine for patients with Mild Cognitive Impairment (MCI) and early-stage AD. The START clinical trial is conducted in collaboration with the Alzheimer's Clinical Trial Consortium (ACTC) and both studies are supported by grant awards totaling $110 million from the National Institute of Aging (NIA).